U.S. Auto Stock News

Wondering whether Definium Therapeutics at US$23.84 is priced for its story or for its fundamentals? This article walks through what the numbers actually say about the stock's value. The share price has recently shown sharp moves, with returns of 8.7% over 7 days, 29.6% over 30 days, 74.8% year to date and 311.0% over the last year, alongside a very large 3 year gain and a 60.5% decline over 5 years. Recent coverage has focused on Definium Therapeutics as a fast moving name in the...

RPM International (RPM) is back in focus after appointing Hexcel chief Thomas C. Gentile III to its board, alongside recent leadership moves in its consumer group that sharpen attention on governance and execution. See our latest analysis for RPM International. The recent leadership additions come as RPM shares trade at US$107.29, with a 30 day share price return of 15.08% contrasting with a 90 day share price return decline of 4.46%, while the 3 year total shareholder return of 40.98% points...

Kyndryl Holdings (KD) just secured a contract with the North Carolina Division of Motor Vehicles to modernize its aging core systems, adding fresh attention to a stock already in focus after recent product launches. See our latest analysis for Kyndryl Holdings. The recent contract win and product launches come as the share price trades at US$14.53, with a 7 day share price return of 10.41% and a 30 day share price return of 19.00%. However, the 1 year total shareholder return shows a 51.29%...

Why Zai Lab Stock Is Back on Investor Radar Zai Lab (NasdaqGM:ZLAB) has drawn fresh attention after a recent swing in performance, with the share price up over the past month and past 3 months, putting its biopharma pipeline back in focus for investors. See our latest analysis for Zai Lab. The recent 30 day share price return of 35.10% and 90 day share price return of 29.72% contrast with a 1 year total shareholder return of 24.87% and 5 year total shareholder return of 86.21%. This indicates...

Avnet stock performance snapshot Avnet (AVT) has drawn fresh attention after a strong run, with the share price at $75.26 and total returns of 28.76% over the past month and 47.83% over the past 3 months. See our latest analysis for Avnet. That recent 28.76% 1 month share price return and 47.83% 3 month share price return sit within a longer stretch of firm gains, with a 59.40% 1 year total shareholder return and 101.15% 3 year total shareholder return indicating sustained momentum. If you...

For investors considering whether Natera at around US$205 per share still offers value, or whether the recent run has already priced in the story, this article focuses on a straightforward question: what you are paying versus what you might be getting. The stock has been volatile recently, with a 4.3% decline over the past 7 days, a 5.2% gain over 30 days, and returns of a 10.2% decline year to date but 42.0% over 1 year and very large gains over 3 years. Recent news coverage has centered on...

Wondering whether HP's current share price reflects its true worth, or if the market is missing something important about this long established name in tech? HP's share price recently closed at US$21.09, with returns of 11.1% over 7 days and 15.4% over 30 days, while the 1 year return sits at an 8.4% decline and the 5 year return at a 26.7% decline. Recent coverage has focused on HP's position within the broader tech sector and how investors are reassessing established hardware and services...

Pony AI (NasdaqGS:PONY) launched PonyWorld 2.0, a major upgrade to its autonomous driving software platform, introducing self-diagnosis and targeted AI training capabilities. The company also began commercial robotaxi operations in Croatia through a joint deployment with Uber and Verne, marking its first commercial service in Europe. These developments combine a new technology stack with a live ride hailing partnership, linking product progress to real world usage. Pony AI focuses on...

Jazz Pharmaceuticals has already presented six new clinical data abstracts on Epidiolex and Xywav at the 2026 American Academy of Neurology Annual Meeting in Chicago, including an oral presentation from the ongoing EpiCom Phase 3b/4 study in tuberous sclerosis complex–associated seizures. The new findings, highlighting caregiver- and clinician-reported behavioral improvements with Epidiolex and enhanced functional outcomes with higher-dose Xywav, underscore how Jazz is aiming to deepen the...

For investors wondering whether Ulta Beauty at about US$570 a share is offering value or stretching expectations, this article walks through what the current price might imply for you as a shareholder. The stock has returned 7.0% over the last week, 7.6% over the last month, an 8.0% decline year to date, and 50.6% over the past year, which can influence how the market views both its potential and its risks. Recent attention on Ulta Beauty has focused on its role as a major U.S. beauty...

Campbell's (NasdaqGS:CPB) has introduced the "Connection Keeper," a storytelling device created with nonprofit StoryCorps to encourage family conversations at mealtimes. The launch highlights Campbell's focus on togetherness and social connection, expanding its activity beyond core packaged food products. This brand-led initiative uses a physical product and nonprofit partnership to keep Campbell's tied to everyday family routines. For investors watching Campbell's at a share price of...

Sana Biotechnology and Mayo Clinic recently announced a collaboration to advance SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes, with Mayo contributing clinical expertise and making an initial US$25,000,000 equity investment plus an option for additional funding. The partnership aims to create standardized, scalable protocols for handling, delivering, and monitoring SC451 across diverse care settings, potentially strengthening both organizations’ roles in...

Over the last 7 days, the United States market has risen by 1.3% and is up 35% over the past year, with earnings expected to grow by 16% annually in the coming years. In this environment of robust growth, identifying stocks that are potentially undervalued can offer opportunities for investors seeking value amidst a rising market.

In April 2026, NASA selected Synopsys, Inc. and EMA to use advanced Ansys simulation tools and ground-based testing to verify Artemis lunar spacesuit compatibility with the Moon’s plasma and regolith environment, while also working with Cesium and NASA’s Glenn Research Center to model lunar communications coverage using Synopsys’ digital mission engineering platform. This collaboration highlights how Synopsys’ chip-to-systems simulation capabilities are being applied to high-stakes aerospace...

If you are wondering whether Himax Technologies at around US$11.64 still offers value, it helps to line up the recent share price performance against what the fundamentals suggest the business might be worth. The stock has posted returns of 16.6% over the past 7 days, 35.5% over 30 days, 36.5% year to date, 90.0% over 1 year, 107.4% over 3 years and 12.9% over 5 years, which naturally raises questions about how much of the story is already reflected in the price. Recent coverage has focused...

Wondering whether Brookfield Infrastructure Partners at around US$36.12 is offering fair value or a potential mispricing opportunity right now? The stock has had mixed short term moves, with a 3% decline over the last 7 days and a 1% decline over the last month, yet it still shows returns of 5.3% year to date and 31.8% over the past year. Recent coverage has focused on Brookfield Infrastructure Partners as a global owner and operator of essential infrastructure. Commentary often highlights...

The United States market has experienced a robust performance, rising 1.3% over the last week and 35% over the past year, with earnings anticipated to grow by 16% annually. In this thriving environment, growth companies with significant insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business's operations and future prospects.

SLB is working with Bahrain to deploy a physics native AI platform that targets system wide optimization of the country's upstream production. The company is also supplying a high pressure, high temperature multiphase subsea boosting system for a major Gulf of America development through its OneSubsea unit. Both projects highlight SLB's focus on digital energy management and advanced subsea engineering beyond routine contract wins. For investors tracking NYSE:SLB, these updates sit...

Over the last 7 days, the U.S. market has risen 1.3%, and over the past year, it is up by an impressive 35%, with earnings forecasted to grow annually by 16%. In light of these robust market conditions, identifying stocks with strong fundamentals becomes crucial for investors seeking stability and growth. While penny stocks might seem like a relic from past trends, they continue to offer intriguing opportunities in smaller or newer companies that demonstrate financial resilience and potential...

Why Sempra (SRE) Is On Investors’ Radar Today Sempra (SRE) is drawing fresh attention after recent share moves, with the stock showing a small 1 day decline, a wider pullback over the past week, but gains over the month and past 3 months. See our latest analysis for Sempra. At a share price of $93.15, Sempra’s recent 7 day share price pullback sits against a 30 day gain of 1.56% and a 90 day share price return of 8.34%, while its 1 year total shareholder return of 32.75% highlights stronger...

Wondering whether J. M. Smucker is attractively priced at today's levels, or if the stock still looks expensive for your portfolio? The share price closed at US$95.74, with a 3.8% gain over the last week, a 3.7% decline over the past month, and returns of 0.9% decline year to date and 15.4% decline over the last year. These moves come as investors continue to reassess long term expectations for the business and sentiment around the wider Food industry. This shapes how much they are willing...

Progressive (PGR) is back in focus after first quarter 2026 earnings, with revenue of US$22.19b and net income of US$2.82b, compared with US$20.41b and US$2.57b a year earlier. See our latest analysis for Progressive. At a share price of US$207.50, Progressive has seen a 5.55% 7 day share price return following its first quarter results, while its year to date share price return of a 2.18% decline contrasts with a 5 year total shareholder return of 132.28%. If these earnings have you...

The United States market has shown robust performance, rising 1.3% over the last week and 35% over the past year, with earnings expected to grow by 16% annually. In such a dynamic environment, identifying small-cap stocks like Alto Ingredients that have strong growth potential and unique market positions can be key to uncovering hidden opportunities.

Wondering if EPR Properties at about US$56.56 is still offering value after its recent run, or if most of the easy gains are already behind it. The stock shows returns of 0.9% over 7 days, 12.1% over 30 days, 11.4% year to date, 22.1% over 1 year, 72.7% over 3 years, and 66.0% over 5 years, which provides useful context before weighing up what the current price might imply. Recent coverage around EPR Properties has focused on its role within the Specialized REITs space and investor interest...